Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

  1. Aix, S.P.
  2. Ciuleanu, T.E.
  3. Navarro, A.
  4. Cousin, S.
  5. Bonanno, L.
  6. Smit, E.F.
  7. Chiappori, A.
  8. Olmedo, M.E.
  9. Horvath, I.
  10. Grohé, C.
  11. Farago, A.F.
  12. López-Vilariño, J.A.
  13. Cullell-Young, M.
  14. Nieto, A.
  15. Vasco, N.
  16. Gómez, J.
  17. Kahatt, C.
  18. Zeaiter, A.
  19. Carcereny, E.
  20. Roubec, J.
  21. Syrigos, K.
  22. Lo, G.
  23. Barneto, I.
  24. Pope, A.
  25. Sánchez, A.
  26. Kattan, J.
  27. Zarogoulidis, K.
  28. Waller, C.F.
  29. Bischoff, H.
  30. Juan-Vidal, O.
  31. Reinmuth, N.
  32. Dómine, M.
  33. Paz-Ares, L.
  34. +
Journal:
The Lancet Respiratory Medicine

ISSN: 2213-2619,  2213-2600

Year of publication: 2023

Volume: 11

Issue: 1

Pages: 74-86

Type: Article

DOI: 10.1016/S2213-2600(22)00309-5 GOOGLE SCHOLAR